Montelukast Treatment Guidelines

Introduction to Montelukast

• Montelukast is approved by the FDA for both seasonal and perennial allergic rhinitis, according to the Journal of Allergy and Clinical Immunology 1

Clinical Context and Positioning

• The American College of Allergy, Asthma, and Immunology states that montelukast is less effective than intranasal corticosteroids for allergic rhinitis, as reported in the Annals of Internal Medicine 3
• Intranasal corticosteroids should be recommended over montelukast for initial treatment of seasonal allergic rhinitis, as stated in the Annals of Internal Medicine 3
• Montelukast is particularly valuable for patients with both asthma and allergic rhinitis, as it addresses both conditions simultaneously, according to the Journal of Allergy and Clinical Immunology 1

Administration and Onset of Action

• Montelukast begins producing clinical benefits by the second day of daily treatment, which is slower than antihistamines, as reported in Praxis Medical Insights: Practical Summaries of Clinical Guidelines 2
• The medication provides continuous control rather than acute symptom relief, according to Praxis Medical Insights: Practical Summaries of Clinical Guidelines 2
• Evening administration is recommended for asthma based on pharmacodynamic profile, as stated in Praxis Medical Insights: Practical Summaries of Clinical Guidelines 2